Source:http://linkedlifedata.com/resource/pubmed/id/12630665
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2003-3-12
|
pubmed:abstractText |
We have examined whether peritumoral administration of IFN-gamma can inhibit growth of HPV16-associated, MHC class I- tumour MK16/1/IIIABC (MK16) transplanted in syngeneic mice. It has been found that peritumoral administration of recombinant IFN-gamma performed on days 0-11 after tumour challenge inhibited growth of MK16 s.c. tumour transplants. If the therapy with IFN-gamma was started when the tumours had already reached a palpable size, the IFN-gamma administration was without any effect. To investigate the antitumour effects of IFN-gamma in a clinically more relevant setting, surgical minimal residual tumour disease was utilized. Subcutaneously growing MK16 carcinomas, 8-12 mm in diameter, were removed and the operated mice were injected with IFN-gamma on days 3-14 after the operation at the site of surgery. Treatment with IFN-gamma resulted in a moderate, reproducible, but statistically insignificant inhibition of tumour recurrences. In the next experiments we have addressed the question whether the tumour-inhibitory effect of IFN-gamma was due to the upregulation of MHC class I molecule expression on MK16 tumour cells. IFN-gamma-treated and control mice were sacrificed, their tumours were explanted, and the expression of MHC class I molecules on the MK16 tumour cells was examined. As presumed, the MHC class I expression on the cells of IFN-gamma-treated tumours, as well as on their lung metastases, was upregulated. However, an unexpected moderate upregulation of the MHC class I expression was also observed on MK16 tumours from the control, exogenous IFN-gamma-uninjected mice. Cytofluorometric analysis of the in vivo transplanted MK16 tumours from both groups has excluded that the increased percentage of the MHC class I molecules on the tumour cell populations could be due to the infiltration of the tumours with MHC class I+ leukocytes, since no expression of MHC class II, CD11b, CD80/CD86, and CD11c molecules in the MK16 cell population was observed.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0015-5500
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
49
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
26-32
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:12630665-Animals,
pubmed-meshheading:12630665-Antiviral Agents,
pubmed-meshheading:12630665-Histocompatibility Antigens Class I,
pubmed-meshheading:12630665-Interferon-gamma,
pubmed-meshheading:12630665-Male,
pubmed-meshheading:12630665-Mice,
pubmed-meshheading:12630665-Neoplasms, Experimental,
pubmed-meshheading:12630665-Papillomaviridae,
pubmed-meshheading:12630665-Papillomavirus Infections,
pubmed-meshheading:12630665-Tumor Virus Infections
|
pubmed:year |
2003
|
pubmed:articleTitle |
Local IFN-gamma therapy of HPV16-associated tumours.
|
pubmed:affiliation |
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|